GE HealthCare reported a strong fourth quarter and full year 2025, exceeding revenue and EPS expectations with notable growth in key segments like Pharmaceutical Diagnostics and Imaging. The company demonstrated operational resilience amidst dynamic macro environments and tariff impacts, focusing on strategy execution, innovation, and productivity improvements.
Total revenues of $5.7 billion in Q4, up 7.1% YoY, with Organic revenue growth of 4.8%.
positiveFull year 2025 revenues of $20.6 billion, up 4.8% YoY, with Organic revenue growth of 3.5%.
positiveDiluted EPS of $1.29 in Q4 and $4.55 for the full year, exceeding expectations.
positivePharmaceutical Diagnostics segment revenue grew 22.3% YoY in Q4.
positiveIntroduced 2026 guidance with projected organic revenue growth of 3.0% to 4.0% and Adjusted EBIT margin expansion of 50 bps to 80 bps.
positiveQ4 Net income attributable to GE HealthCare decreased to $589 million from $720 million YoY.
negativeQ4 Net income margin of 10.3% decreased by 320 bps YoY, and Adjusted EBIT margin of 16.7% decreased by 200 bps YoY, negatively impacted by tariff expense and unfavorable mix.
negativePatient Care Solutions segment revenue decreased 0.3% YoY in Q4, with a 1.1% organic decrease.
attentionSegment EBIT for Imaging decreased 12.5% YoY in Q4, and for Patient Care Solutions decreased 29.6% YoY.
negativeFull year 2025 Adjusted EBIT margin of 15.3% decreased by 100 bps YoY.
negativeFull year Free cash flow of $1.5 billion decreased by 3.2% YoY.
attentionMargin expansion indicates improving profitability and operational efficiency. Measured in basis points (bps): 100 bps = 1.0%.
| Segment | Current | Prior Yr | YoY | % Total | CC |
|---|---|---|---|---|---|
Imaging | N/A | — | — | — | +5.3% |
Advanced Visualization Solutions | N/A | — | — | — | +4.2% |
Patient Care Solutions | N/A | — | — | — | -1.1% |
Pharmaceutical Diagnostics | N/A | — | — | — | +12.7% |
| Total Revenue | $0.00M | — | — | 100.0% | — |
Segment performance shows business unit health and growth drivers. Constant currency (CC) removes FX impact for like-for-like comparison.
Forward-looking guidance is subject to change and does not constitute a guarantee. Actual results may differ materially from these estimates.
Delivered a strong quarter and year with growth in Pharmaceutical Diagnostics, Imaging, and Advanced Visualization Solutions.
Advanced Heartbeat, our proprietary business system, to improve the customer experience and drive productivity to deliver margin expansion.
Entered 2026 with momentum driven by a differentiated innovation pipeline.
Commentary excerpts from earnings call transcripts provide management's perspective on performance, strategy, and outlook. Always review full transcripts for complete context.
Operational metrics provide insight into business drivers and customer engagement beyond traditional financial measures.